Sensei Biotherapeutics (SNSE) AI Stock Analysis

• Market Cap: $9.93M
• Dividend Yield: N/A
• Average Volume (3M): 5.29M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.18
• Revenue Growth: N/A
• EPS Growth: 1.00%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): -1.20
• Shares Outstanding: 25,208,069
• 10 Day Avg. Volume: 15,710,010
• 30 Day Avg. Volume: 5,293,481
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 33.31
• Price to Cash Flow (P/CF): -0.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.00
• Price Target Upside: 925.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Sensei Biotherapeutics has a low overall stock score, driven primarily by weak financial performance marked by a lack of revenue and persistent losses. The promising clinical trial results provide a positive outlook, but the company's financial instability and negative valuation metrics weigh heavily on the score. Technical indicators provide some support, but are not enough to offset the financial concerns.

Positive Factors

Clinical Trial Developments

Sensei Biotherapeutics has reported compelling preliminary dose expansion data for solnerstotug in patients with advanced solid tumors, showing a high disease control rate.

Financial Outlook

Sensei's cash runway has been extended into 2Q26 due to corporate restructuring.

Regulatory Progress

SNS-101 could potentially be the first anti-VISTA monoclonal antibody approved as a therapeutic agent, with an anticipated launch in 2029.

Negative Factors

Clinical Efficacy Concerns

No complete or partial responses were observed in patients with 'cold' tumors, as expected, indicating limited efficacy in this group.

Earnings

Sensei reported 4Q24 EPS of ($0.31), compared to an estimate of ($0.29).

Regulatory Challenges

The anticipated data update for the SNS-101 study has been delayed to 1H25, as the company seeks more duration data.

Sensei Biotherapeutics Business Overview & Revenue Model

Company Description

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

How the Company Makes Money

Sensei Biotherapeutics makes money primarily through the development and potential commercialization of its proprietary immunotherapy products. The company's revenue model is centered around advancing its product candidates through clinical trials, with the ultimate goal of gaining regulatory approval for commercialization. Key revenue streams may include licensing agreements, collaborations, and partnerships with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on future sales of their developed therapies. Additionally, Sensei may secure funding through grants and research collaborations that support its R&D efforts. However, as a clinical-stage company, Sensei is primarily focused on research and development activities and may not yet have significant product sales revenue.

Sensei Biotherapeutics Financial Statement Overview

Summary

Sensei Biotherapeutics faces significant financial challenges, primarily due to a lack of revenue and ongoing net losses. The negative cash flows and profitability metrics overshadow some balance sheet improvements, such as reduced debt levels.

Income Statement

Sensei Biotherapeutics has not generated any revenue over the past years, which is a significant concern. The company has consistently reported net losses, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies and high operational costs relative to nonexistent revenue.

Balance Sheet

The company's balance sheet shows a moderate level of debt with a debt-to-equity ratio that has improved over time due to a reduction in liabilities and an increase in equity. However, the negative net income impacts the return on equity, and the equity ratio is under pressure due to declining total assets. The improvement in net debt indicates better cash management, but the overall equity position remains weak.

Cash Flow

Operating cash flow is negative, indicating that the company is not generating sufficient cash from its core operations. Free cash flow is consistently negative, which could pose liquidity challenges. The company has been reliant on financing activities to sustain operations, which is not sustainable in the long term without revenue generation.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.85M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
2.44M	0.00	-571.00K	-1.81M	-685.00K	-209.00K
	EBIT
-32.48M	-32.61M	-37.06M	-50.19M	-37.48M	-19.45M
	EBITDA
-28.96M	-32.61M	-33.39M	-46.56M	-36.80M	-18.50M
	Net Income Common Stockholders
-29.80M	-30.16M	-34.10M	-48.81M	-37.46M	-20.63M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
58.08M	41.34M	65.76M	17.80M	147.62M	16.60M
	Total Assets
66.69M	45.36M	74.37M	118.38M	153.22M	21.43M
	Total Debt
5.64M	3.85M	6.21M	8.03M	2.35M	567.00K
	Net Debt
-5.32M	-6.15M	-6.80M	-9.76M	-4.80M	-16.03M
	Total Liabilities
8.22M	6.97M	9.48M	14.97M	6.71M	77.87M
	Stockholders Equity
58.47M	38.39M	64.89M	103.41M	146.51M	-56.44M
Cash Flow		Free Cash Flow
-25.19M	-24.82M	-32.20M	-39.35M	-32.28M	-18.91M
	Operating Cash Flow
-25.04M	-24.67M	-32.02M	-39.03M	-30.26M	-17.70M
	Investing Cash Flow
33.85M	22.44M	38.41M	49.95M	-143.12M	-1.40M
	Financing Cash Flow
-1.02M	-787.00K	-11.17M	-287.00K	163.94K	35.45M

Sensei Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNSE, the sentiment is Negative. The current price of 0.39 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.46, and below the 200-day MA of 0.54, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 34.63 is Neutral, neither overbought nor oversold. The STOCH value of 23.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNSE.

Sensei Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
ADAP	46 Neutral	$50.42M	―	-273.36%	―	194.23%	45.50%
SNSE	45 Neutral	$9.93M	―	-58.40%	―	―	1.00%
IMTX	45 Neutral	$552.62M	55.96	3.73%	―	188.64%	―
FATE	42 Neutral	$97.33M	―	-54.21%	―	-78.55%	-0.92%
ALLO	41 Neutral	$317.21M	―	-55.13%	―	-86.25%	36.10%

Sensei Biotherapeutics Corporate Events

Sensei Biotherapeutics Reports Promising Phase 1/2 Trial Results

On March 27, 2025, Sensei Biotherapeutics announced favorable preliminary results from the dose expansion portion of its Phase 1/2 trial for solnerstotug, a monoclonal antibody targeting VISTA, in PD-(L)1 resistant tumors. The trial showed an overall response rate nearly three times higher than historical PD-(L)1 rechallenge rates, with notable responses observed in Merkel Cell Carcinoma and MSI-H Colorectal Cancer patients. These findings suggest solnerstotug may offer a significant clinical benefit in select tumor types. The company plans to initiate a Phase 2 study in early 2026, contingent on securing sufficient capital, with ongoing analyses to optimize trial design and patient selection.